DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of RoActemra/Actemra (Tociliumab) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy

Information source: Hoffmann-La Roche
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Spondylitis, Ankylosing

Intervention: tocilizumab [RoActemra/Actemra] (Drug); tocilizumab [RoActemra/Actemra] (Drug); Placebo (Drug); tocilizumab [RoActemra/Actemra] (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Hoffmann-La Roche

Official(s) and/or principal investigator(s):
Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche

Overall contact:
Please reference Study ID Number: WA22908, Phone: 888-662-6728 (U.S. Only), Email: genentechclinicaltrials@druginfo.com

Summary

This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis who have had an inadequate response to previous TNF antagonist therapy. Patients will be randomized to receive RoActemra/Actemra at a dose of either 8 mg/kg or 4mg/kg intravenously (iv) or placebo every 4 weeks for 24 weeks. The double-blind treatment period will be followed by open-label treatment with RoActemra/Actemra 8 mg/kg iv every 4 weeks until Week 104 for all patients. Anticipated time on study treatment is 104 weeks.

Clinical Details

Official title: A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Proportion of patients achieving response of 20% improvement in ASsessment in AS International Working Group criteria (ASAS20)

Safety: Adverse events, laboratory parameters

Secondary outcome:

Long-term efficacy according to the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Metrology Index (BASMI)

Pharmacokinetics and pharmacodynamics (tocilizumab AUC, Cmax, T1/2, Cl, V; Interleukin-6; Soluble Il-6 receptor)

Immunogenicity: anti-tocilizumab antibodies

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Ankylosing Spondylitis as defined by the modified New York criteria for >/= 3 months

prior to baseline

- Active disease at screening and baseline (BASDAI >/= 4. 0, spinal pain VAS >/=40)

- Inadequate response or intolerant to 1 or more previous non-steroidal anti-rheumatic

drugs (NSAIDs)

- Inadequate response to treatment with etanercept, infliximab, adalimumab or golimumab

because of inadequate efficacy

- TNF antagonist therapy must have been discontinued at least 8 weeks prior to baseline

(etanercept 4 weeks)

- Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at

least 4 weeks prior to baseline (methotrexate, sulfasalazine and hyroxychloroquine or chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline)

- Oral corticosteroids (>/= 10 mg/day prednisone or equivalent) and NSAIDs/COX-2

inhibitors must be at stable dose for at least 4 weeks prior to baseline

Exclusion Criteria:

- Major surgery (including joint surgery) within 8 weeks prior to screening or planned

major surgery within 6 months after randomization

- Total ankylosis of spine (as determined by investigator)

- Inflammatory rheumatic disease other than ankylosing spondylitis

- Active, acute uveitis at baseline

- Previous treatment with RoActemra/Actemra

- Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks

prior to screening

- History of severe allergic or anaphylactic reactions to humanized or murine

monoclonal antibodies

- Active current or history of recurrent bacterial, viral, fungal, mycobacterial or

other infection

- History of or currently active primary or secondary immunodeficiency

- Body weight > 150 kg

Locations and Contacts

Please reference Study ID Number: WA22908, Phone: 888-662-6728 (U.S. Only), Email: genentechclinicaltrials@druginfo.com

Additional Information

Starting date: October 2010
Last updated: September 28, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014